The unwanted effects count, too
PT-141 is also called bremelanotide. In the controlled trials, nausea, flushing and headache were common alongside the improvements in desire and distress. Those effects also appeared in the longer follow-up, where nausea was the main problem with tolerating treatment.
That's part of the result, not something to get past before returning to the benefit. A change in desire may matter to someone. So may feeling too unwell to enjoy the day. There's room to ask about both.
Blood pressure is a firm limit
The approved prescribing information warns that bremelanotide can temporarily raise blood pressure and lower heart rate. Under the label, it must not be used by someone with uncontrolled high blood pressure or known cardiovascular disease. The medical word is contraindicated: the medicine must not be used in those circumstances.
An article can't check that history for you. A clinician needs to hear about your health and other medicines, including things that might seem unrelated to a question about desire. Feeling well today doesn't answer every safety question.
Skin changes can last
The label also warns about skin darkening, including areas such as the gums. More frequent use and darker skin are associated with greater risk. The change may not fully fade after treatment stops.
That's worth a direct question in a consultation. What could change, how lasting might it be, and who would assess a problem? This page doesn't turn the warning into a schedule for trying to avoid it.
A less common concern
The LiverTox safety review reports mild rises in liver-related blood markers and rare cases of liver injury. Rare doesn't mean likely, but this concern belongs in the discussion, especially when someone already has liver problems.
A clinician can put that information alongside the rest of your history. A list of side effects can't tell us which concern will matter most to a particular person.
The label on the material matters
Forensic testing found bremelanotide in seized illicit samples. A research-use label isn't evidence that material is suitable for human use.
Compounded medicines have a separate limitation: FDA doesn't approve them or verify their safety, effectiveness and quality before marketing. A familiar ingredient name doesn't settle the preparation's safety.
Questions about pregnancy plans, breastfeeding, other medicines and follow-up belong with the clinician. The trial results can help frame that conversation. They can't provide an individual safety assessment.